In vivo, administration of an IL-18BP alleviated DSS-induced colitis [201] and single knockout of IL-18 (as well as double knockout together with IL-1β) protected against dinitrobenzene sulfonic acid (DNBS)-induced colitis [202]. Here, IL18 is linked to colitis.